Soligenix, Inc. Common Stock (SNGX)
Soligenix, Inc. is a biotechnology company focused on developing and commercializing innovative products in the areas of infectious disease, oncology, and gastrointestinal disorders. The company leverages its proprietary ThermoVax vaccine thermosensitive platform and other advanced technologies to develop therapies and vaccines, aiming to address unmet medical needs through research and development efforts.
Company News
Soligenix, a late-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, with an on-demand presentation available on September 5th.
The non-Hodgkin's lymphoma market is expected to grow significantly between 2025-2034, driven by increasing incidence, advancements in targeted therapies, emerging treatments, and improved early detection efforts.
Soligenix reported positive interim data from a trial of its HyBryte therapy, with three out of six enrolled patients meeting the success criteria. The company plans to enroll a total of 50 patients and is working towards a confirmatory Phase 3 study.
Here's 3 steps to take prior to trading penny stocks in 2024 The post Don’t Trade Penny Stocks Until You’ve Taken These Steps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.